Format

Send to

Choose Destination
Eur J Ophthalmol. 2011 Mar-Apr;21(2):156-61.

Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases.

Author information

1
Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey. byeniad@yahoo.com

Abstract

PURPOSE:

To investigate the inflammation of the anterior chamber after intravitreal bevacizumab injection in different ocular exudative diseases.

METHODS:

The study included 76 eyes from 62 consecutive patients with different ocular exudative diseases. The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). The study also included 32 age-matched control patients. Inflammation of the anterior chamber was examined with flare-cell photometry before and after an intravitreal injection of 1.25 mg of bevacizumab.

RESULTS:

There were no statistically significant differences between the measurements at baseline and postoperative day 1, 3, 7, or 30 in any of the groups (p>0.05).

CONCLUSIONS:

The extent of inflammation in the anterior chamber did not change after intravitreal bevacizumab injection in patients with nonproliferative diabetic retinopathy, choroidal neovascularization secondary to age-related macular degeneration, or macular edema due to branch or central vein occlusion.

PMID:
20658459
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center